Document is current
Any future updates will be listed below
-
Authors
Karlsson, Linda https://orcid.org/0000-0002-0630-772X
Vogel, Jacob
Arvidsson, Ida https://orcid.org/0009-0007-6065-8639
Åström, Kalle
Janelidze, Shorena
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Stomrud, Erik
Mattsson-Carlgren, Niklas
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 13 June 2023
Accepted: 17 April 2024
First Online: 1 May 2024
Competing interests
: OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. SP has acquired research support (for the institution) from ki elements / ADDF. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Lilly, and Roche. The remaining authors declare no competing interests.
